
The US-based pharma giant, which has already advanced its schedule of starting human trials of its candidate vaccine to the second half of July from September, is working on the twin fronts of expanding existing manufacturing capacity and establishing new units, Chief Scientific Officer Paul Stoffels told PTI.
from Moneycontrol Business News https://ift.tt/3eLb7rZ
No comments:
Post a Comment